• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

MEDCHANNEL Announces U.S. Data Supports DG-HAL and Mucopexy With the HTS(TM)Hemorrhoid Treatment System to Treat Patients With Grades II to IV Hemorrhoids

Posted on: Monday, 30 April 2007, 12:00 CDT

MEDCHANNEL, LLC reports that preliminary data presented at the recent SAGES conference by Dr. Matthew Albert supports the treatment of patients with grade II to IV hemorrhoids with Doppler-guided Hemorrhoid Artery Ligation (DG-HAL) and mucopexy. Dr. Matthew Albert, a board certified colorectal surgeon and member of the Department of Colorectal Surgery at Florida Hospital, Orlando, FL, presented preliminary results using DG-HAL and mucopexy on his first 48 patients.

Approximately 500,000 patients are medically treated for hemorrhoids in the United States every year, with approximately 20% undergoing surgery. Hemorrhoids and traditional treatments are often painful.

The HTS Hemorrhoid Treatment System is the only device of its kind currently approved and commercialized in the United States. The HTS system enables DG-HAL by using Doppler guidance and simple suturing techniques to reduce blood flow to the hemorrhoids, allowing them to shrink and recede. The system also enables mucopexy of prolapsed hemorrhoids (lifting of protruding hemorrhoids) again, with simple suturing techniques; tissue is not cut or removed and both procedures are performed in an area devoid of nerve endings. Thousands of procedures have been performed successfully worldwide with patients reporting significantly less pain.

"While this represents a small group of patients, our results are consistent with the positive outcomes reported in the literature by our international colleagues," said Dr. Albert. "It is my experience that the results are good and that complications rates are low and manageable. It is worth noting that the patients themselves rate the procedure highly." Dr. Albert reported that, of the 48 patients treated, 50% were grade III and 10% were grade IV. Forty-eight percent had mucopexy in addition to DG-HAL. At six weeks follow-up examination, 96% had complete resolution of bleeding, 93% were pain-free and 90% of patients who had DG-HAL and mucopexy had resolution of prolapse; 98% of patients reported improvement of symptoms on their follow-up questionnaire and 95% would recommend the procedure to other patients.

Dr. Steven Schwaitzberg, Program Chairman of SAGES and Chief of Surgery at the Cambridge Hospital, Cambridge, MA, commented, "Dr. Albert's results and reports in the literature are compelling, this is certainly a therapeutic option that shows great promise and should be included in the armamentarium to treat hemorrhoid disease." Cambridge Hospital has recently implemented an HTS system to treat patients.

"It is our goal to seek out and bring to market the best new and innovative technologies to treat patients, the HTS Hemorrhoid Treatment System is a perfect example of such a device," said R. Michael Dudley, President and CEO of MEDCHANNEL. "This device has been used to successfully treat thousands of patients in Europe, now hemorrhoid sufferers in the U.S. have this treatment option available to them."

MEDCHANNEL provides sales and marketing channels or a complete outsourced business model for medical device Technology Partners. For more information, please visit: www.medchannel.com.

This press release contains forward-looking statements with respect to MEDCHANNEL. MEDCHANNEL wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and introduction, clinical trials, intellectual property, regulatory approvals, competitive offerings, base research, integration of acquired companies, the Company's overall business strategy, and other factors. HTS is a trademark of MEDCHANNEL, LLC.

Source: Business Wire

More News in this Category